The Athlete's Edge: How One Biotech Startup Is Mining Elite Athletes' Gut Bacteria To Create Next-Gen Probiotics

Q: How long will it take to read this news story?

The story "The Athlete&#039;s Edge: How One Biotech Startup Is Mining Elite Athletes&#039; Gut Bacteria To Create Next-Gen Probiotics" has 21 words across 87 sentences, which will take approximately 1 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "The Athlete&#039;s Edge: How One Biotech Startup Is Mining Elite Athletes&#039; Gut Bacteria To Create Next-Gen Probiotics" was covered 16 hours ago by Forbes, a news publisher based in United States.

Q: How trustworthy is 'Forbes' news outlet?

Forbes is a fully independent (privately-owned) news outlet established in 1917 that covers mostly startups and technology news. The outlet is headquartered in United States and publishes an average of 73 news stories per day. It's most recent story was published 15 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23704976</li><li>URL: https://beamstart.com/news/the-athletes-edge-how-one-17320447015111</li></ul>

Forbes Logo Forbes 16h ago

The Athlete's Edge: How One Biotech Startup Is Mining Elite Athletes' Gut Bacteria To Create Next-Gen Probiotics - Forbes

Quick Summary:

"Traditional biotech really is 10 years and billions of dollars to develop drugs with less than a 10% success rate," explains Scheiman, who completed his postdoctoral research in George Church's lab at Harvard.

"We looked at ultra-marathon runners that run 100 miles at a time, and we found this microorganism called Veillonella that naturally eats lactic acid to fight fatigue and promote endurance," Scheiman explains.

In terms of health tech companies that create, translate, and sell their own IP, the list is much shorter; Debut Bio and Arcaea are considered synbio companies that use biotech for consumer health.